Surface-Engineered Monocyte Immunotherapy Combined Graphene Quantum Dots Effective Against Solid Tumor Targets

Overview

Journal Int J Nanomedicine

Publisher Dove Medical Press

Specialty Biotechnology

Date 2023 May 1

PMID 37122502

Authors

Qing Xia

Yue Tang

Wang Li

Tingting Liang

Yue Zhou

Jun Liu

Feila Liu

Affiliations

Soon will be listed here.

Abstract

Introduction: The immunosuppressive tumor microenvironment (TME) of solid tumors inhibits most drug delivery system-based nanomaterials from achieving deep penetration in tumor tissue and interferes with T cell activity in terms of differentiation and exhaustion, which is becoming a critical therapy hurdle for solid tumors. Therefore, developing a therapeutic strategy with abilities of rapid establishment of tumor-targeted cells, elimination of immune obstacles, and enhanced active immunization is very important, while is still a big challenge.

Methods: A new strategy was explored to enhance immune therapy via the conjugation of microRNA155 (miR) to the surface of therapeutic monocyte with graphene quantum dots (GQDs).

Results: TME was reversed using surface-engineered monocyte immunotherapy via reprogramming pro-tumoral M2 TAMs into antitumor M1, and thus tumor elimination was dramatically enhanced.

Conclusion: Such a surface-engineered monocyte immunotherapy has been demonstrated to be well tolerated to intravenous administration and bio-compatible, showing the potential to be extended for the solid tumor treatment.

Citing Articles

Quantum Dots as a Potential Multifunctional Material for the Enhancement of Clinical Diagnosis Strategies and Cancer Treatments.

Guo W, Song X, Liu J, Liu W, Chu X, Lei Z Nanomaterials (Basel). 2024; 14(13).

PMID: 38998693 PMC: 11243735. DOI: 10.3390/nano14131088.

Multifunctional nanocomposites modulating the tumor microenvironment for enhanced cancer immunotherapy.

Sharma P, Otto M Bioact Mater. 2023; 31:440-462.

PMID: 37701452 PMC: 10494322. DOI: 10.1016/j.bioactmat.2023.08.022.

Theranostic Applications of 2D Graphene-Based Materials for Solid Tumors Treatment.

Iannazzo D, Celesti C, Giofre S, Ettari R, Bitto A Nanomaterials (Basel). 2023; 13(16).

PMID: 37630966 PMC: 10459055. DOI: 10.3390/nano13162380.

Photothermal therapy using graphene quantum dots.

Dar M, Tabish T, Thorat N, Swati G, Sahu N APL Bioeng. 2023; 7(3):031502.

PMID: 37614868 PMC: 10444203. DOI: 10.1063/5.0160324.

References

Ding X, Sun X, Cai H, Wu L, Liu Y, Zhao Y . Engineering Macrophages Nanotechnology and Genetic Manipulation for Cancer Therapy. Front Oncol. 2022; 11:786913. PMC: 8770285. DOI: 10.3389/fonc.2021.786913. View

McMillin D, Negri J, Mitsiades C . The role of tumour-stromal interactions in modifying drug response: challenges and opportunities. Nat Rev Drug Discov. 2013; 12(3):217-28. DOI: 10.1038/nrd3870. View

Liu Y, Cao X . Immunosuppressive cells in tumor immune escape and metastasis. J Mol Med (Berl). 2015; 94(5):509-22. DOI: 10.1007/s00109-015-1376-x. View

Liu F, Ding N, Huo D, Yang G, Wei K, Guan G . Surface-Engineered Monocyte Inhibits Atherosclerotic Plaque Destabilization via Graphene Quantum Dot-Mediated MicroRNA Delivery. Adv Healthc Mater. 2019; 8(15):e1900386. DOI: 10.1002/adhm.201900386. View

Zheng L, Hu X, Wu H, Mo L, Xie S, Li J . In Vivo Monocyte/Macrophage-Hitchhiked Intratumoral Accumulation of Nanomedicines for Enhanced Tumor Therapy. J Am Chem Soc. 2019; 142(1):382-391. DOI: 10.1021/jacs.9b11046. View

Rausch M, Hastings K . Diverse cellular and organismal functions of the lysosomal thiol reductase GILT. Mol Immunol. 2015; 68(2 Pt A):124-8. PMC: 4623965. DOI: 10.1016/j.molimm.2015.06.008. View

Zhang Y, Choksi S, Chen K, Pobezinskaya Y, Linnoila I, Liu Z . ROS play a critical role in the differentiation of alternatively activated macrophages and the occurrence of tumor-associated macrophages. Cell Res. 2013; 23(7):898-914. PMC: 3698641. DOI: 10.1038/cr.2013.75. View

Chung S, Revia R, Zhang M . Graphene Quantum Dots and Their Applications in Bioimaging, Biosensing, and Therapy. Adv Mater. 2019; 33(22):e1904362. PMC: 7289657. DOI: 10.1002/adma.201904362. View

Joyce J, Fearon D . T cell exclusion, immune privilege, and the tumor microenvironment. Science. 2015; 348(6230):74-80. DOI: 10.1126/science.aaa6204. View

10.

Sawant D, Yano H, Chikina M, Zhang Q, Liao M, Liu C . Adaptive plasticity of IL-10 and IL-35 T cells cooperatively promotes tumor T cell exhaustion. Nat Immunol. 2019; 20(6):724-735. PMC: 6531353. DOI: 10.1038/s41590-019-0346-9. View

11.

Parlakpinar H, Ozer M, Sahna E, Vardi N, Cigremis Y, Acet A . Amikacin-induced acute renal injury in rats: protective role of melatonin. J Pineal Res. 2003; 35(2):85-90. DOI: 10.1034/j.1600-079x.2003.00059.x. View

12.

Franklin R, Liao W, Sarkar A, Kim M, Bivona M, Liu K . The cellular and molecular origin of tumor-associated macrophages. Science. 2014; 344(6186):921-5. PMC: 4204732. DOI: 10.1126/science.1252510. View

13.

Di Pilato M, Kfuri-Rubens R, Pruessmann J, Ozga A, Messemaker M, Cadilha B . CXCR6 positions cytotoxic T cells to receive critical survival signals in the tumor microenvironment. Cell. 2021; 184(17):4512-4530.e22. PMC: 8719451. DOI: 10.1016/j.cell.2021.07.015. View

14.

Essandoh K, Li Y, Huo J, Fan G . MiRNA-Mediated Macrophage Polarization and its Potential Role in the Regulation of Inflammatory Response. Shock. 2016; 46(2):122-31. PMC: 4949115. DOI: 10.1097/SHK.0000000000000604. View

15.

Hong S, Zhang Z, Liu H, Tian M, Zhu X, Zhang Z . B Cells Are the Dominant Antigen-Presenting Cells that Activate Naive CD4 T Cells upon Immunization with a Virus-Derived Nanoparticle Antigen. Immunity. 2018; 49(4):695-708.e4. DOI: 10.1016/j.immuni.2018.08.012. View

16.

Gunassekaran G, Vadevoo S, Baek M, Lee B . M1 macrophage exosomes engineered to foster M1 polarization and target the IL-4 receptor inhibit tumor growth by reprogramming tumor-associated macrophages into M1-like macrophages. Biomaterials. 2021; 278:121137. DOI: 10.1016/j.biomaterials.2021.121137. View

17.

Etxeberria I, Bolanos E, Quetglas J, Gros A, Villanueva A, Palomero J . Intratumor Adoptive Transfer of IL-12 mRNA Transiently Engineered Antitumor CD8 T Cells. Cancer Cell. 2019; 36(6):613-629.e7. DOI: 10.1016/j.ccell.2019.10.006. View

18.

Engblom C, Pfirschke C, Pittet M . The role of myeloid cells in cancer therapies. Nat Rev Cancer. 2016; 16(7):447-62. DOI: 10.1038/nrc.2016.54. View

19.

Arunachalam B, Phan U, Geuze H, Cresswell P . Enzymatic reduction of disulfide bonds in lysosomes: characterization of a gamma-interferon-inducible lysosomal thiol reductase (GILT). Proc Natl Acad Sci U S A. 2000; 97(2):745-50. PMC: 15401. DOI: 10.1073/pnas.97.2.745. View

20.

Saccani A, Schioppa T, Porta C, Biswas S, Nebuloni M, Vago L . p50 nuclear factor-kappaB overexpression in tumor-associated macrophages inhibits M1 inflammatory responses and antitumor resistance. Cancer Res. 2006; 66(23):11432-40. DOI: 10.1158/0008-5472.CAN-06-1867. View